Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $641.00 at HC Wainwright

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective lifted by HC Wainwright from $591.00 to $641.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on VRTX. UBS Group upped their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price on the stock in a research note on Friday, February 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $590.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Royal Bank Of Canada decreased their price objective on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a report on Friday, February 13th. Finally, Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective on the stock in a research report on Tuesday, January 6th. Twenty-three research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $551.77.

Vertex Pharmaceuticals Stock Up 8.3%

Vertex Pharmaceuticals stock opened at $499.17 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.68. The company’s 50 day moving average price is $468.41 and its two-hundred day moving average price is $436.53. The stock has a market cap of $126.80 billion, a P/E ratio of 32.56 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.98 earnings per share. On average, equities analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Activity

In related news, EVP Mark E. Bunnage sold 2,021 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares in the company, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 58,613 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the sale, the executive vice president directly owned 58,934 shares in the company, valued at approximately $27,630,027.22. This trade represents a 49.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is owned by company insiders.

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Earned Wealth Advisors LLC grew its stake in Vertex Pharmaceuticals by 3.3% in the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock valued at $295,000 after buying an additional 21 shares in the last quarter. Confluence Wealth Services Inc. raised its holdings in Vertex Pharmaceuticals by 4.0% during the 4th quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after acquiring an additional 21 shares during the period. Williams Jones Wealth Management LLC. lifted its position in shares of Vertex Pharmaceuticals by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after acquiring an additional 21 shares in the last quarter. Childress Capital Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 3.1% in the fourth quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company’s stock worth $331,000 after acquiring an additional 22 shares during the period. Finally, Central Pacific Bank Trust Division boosted its holdings in shares of Vertex Pharmaceuticals by 0.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 5,026 shares of the pharmaceutical company’s stock worth $2,279,000 after acquiring an additional 24 shares during the period. Institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.